154 related articles for article (PubMed ID: 12123801)
1. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
Karvonen U; Jänne OA; Palvimo JJ
FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
3. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
4. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
5. PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.
Meyer R; Wolf SS; Obendorf M
J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):1-14. PubMed ID: 17587566
[TBL] [Abstract][Full Text] [Related]
6. Co-activator and co-repressor interplay on the human androgen receptor.
Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
[No Abstract] [Full Text] [Related]
7. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Miyamoto H; Yeh S; Wilding G; Chang C
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
[TBL] [Abstract][Full Text] [Related]
8. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
10. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
12. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Kang Z; Jänne OA; Palvimo JJ
Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
[TBL] [Abstract][Full Text] [Related]
13. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
Nguyen TV; Yao M; Pike CJ
Endocrinology; 2007 Jun; 148(6):2936-43. PubMed ID: 17347309
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
[TBL] [Abstract][Full Text] [Related]
15. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
[TBL] [Abstract][Full Text] [Related]
16. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
[TBL] [Abstract][Full Text] [Related]
17. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Steinsapir J; Mora G; Muldoon TG
Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells.
Tyagi RK; Lavrovsky Y; Ahn SC; Song CS; Chatterjee B; Roy AK
Mol Endocrinol; 2000 Aug; 14(8):1162-74. PubMed ID: 10935541
[TBL] [Abstract][Full Text] [Related]
19. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
[TBL] [Abstract][Full Text] [Related]
20. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
